These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30981993)

  • 21. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
    J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overlap between frontotemporal dementia and Alzheimer's disease: cerebrospinal fluid pattern and neuroimaging study.
    Padovani A; Premi E; Pilotto A; Gazzina S; Cosseddu M; Archetti S; Cancelli V; Paghera B; Borroni B
    J Alzheimers Dis; 2013; 36(1):49-55. PubMed ID: 23568100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.
    Landqvist Waldö M; Frizell Santillo A; Passant U; Zetterberg H; Rosengren L; Nilsson C; Englund E
    BMC Neurol; 2013 May; 13():54. PubMed ID: 23718879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel CSF biomarkers for frontotemporal lobar degenerations.
    Hu WT; Chen-Plotkin A; Grossman M; Arnold SE; Clark CM; Shaw LM; McCluskey L; Elman L; Hurtig HI; Siderowf A; Lee VM; Soares H; Trojanowski JQ
    Neurology; 2010 Dec; 75(23):2079-86. PubMed ID: 21048198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration.
    Goossens J; Bjerke M; Van Mossevelde S; Van den Bossche T; Goeman J; De Vil B; Sieben A; Martin JJ; Cras P; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
    Alzheimers Res Ther; 2018 Mar; 10(1):31. PubMed ID: 29559004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
    Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
    JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The power of neuroimaging biomarkers for screening frontotemporal dementia.
    McMillan CT; Avants BB; Cook P; Ungar L; Trojanowski JQ; Grossman M
    Hum Brain Mapp; 2014 Sep; 35(9):4827-40. PubMed ID: 24687814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia.
    Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E
    Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures.
    Falgàs N; Ruiz-Peris M; Pérez-Millan A; Sala-Llonch R; Antonell A; Balasa M; Borrego-Écija S; Ramos-Campoy O; Augé JM; Castellví M; Tort-Merino A; Olives J; Fernández-Villullas G; Blennow K; Zetterberg H; Bargalló N; Lladó A; Sánchez-Valle R
    Hum Brain Mapp; 2020 Jun; 41(8):2004-2013. PubMed ID: 31944489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
    Toledo JB; Brettschneider J; Grossman M; Arnold SE; Hu WT; Xie SX; Lee VM; Shaw LM; Trojanowski JQ
    Acta Neuropathol; 2012 Jul; 124(1):23-35. PubMed ID: 22526019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders.
    Bourbouli M; Rentzos M; Bougea A; Zouvelou V; Constantinides VC; Zaganas I; Evdokimidis I; Kapaki E; Paraskevas GP
    Dement Geriatr Cogn Disord; 2017; 44(3-4):144-152. PubMed ID: 28848086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma proteome profiling identifies changes associated to AD but not to FTD.
    Mofrad RB; Del Campo M; Peeters CFW; Meeter LHH; Seelaar H; Koel-Simmelink M; Ramakers IHGB; Middelkoop HAM; De Deyn PP; Claassen JAHR; van Swieten JC; Bridel C; Hoozemans JJM; Scheltens P; van der Flier WM; Pijnenburg YAL; Teunissen CE
    Acta Neuropathol Commun; 2022 Oct; 10(1):148. PubMed ID: 36273219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration.
    Cousins KAQ; Irwin DJ; Wolk DA; Lee EB; Shaw LMJ; Trojanowski JQ; Da Re F; Gibbons GS; Grossman M; Phillips JS
    Brain; 2020 Jul; 143(7):2295-2311. PubMed ID: 32666090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CSF biomarkers in frontotemporal lobar degeneration with known pathology.
    Bian H; Van Swieten JC; Leight S; Massimo L; Wood E; Forman M; Moore P; de Koning I; Clark CM; Rosso S; Trojanowski J; Lee VM; Grossman M
    Neurology; 2008 May; 70(19 Pt 2):1827-35. PubMed ID: 18458217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP.
    Hu WT; Watts K; Grossman M; Glass J; Lah JJ; Hales C; Shelnutt M; Van Deerlin V; Trojanowski JQ; Levey AI
    Neurology; 2013 Nov; 81(22):1945-52. PubMed ID: 24174584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.